

Drug and Biologic Coverage Policy



Effective Date 1/1/2024
Next Review Date... 1/1/2025
Coverage Policy Number IP0576

Somapacitan

Table of Contents

Overview	1
Medical Necessity Criteria	1
Reauthorization Criteria	4
Authorization Duration	4
Conditions Not Covered.....	5
Background.....	7
References	8

Related Coverage Resources

[Somatropin - \(IP0452\)](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for somapacitan-beco subcutaneous injection (**Sogroya**[®]).

Additional criteria that support the review for medical necessity exceptions of non-covered products are located in the [Non-Covered Product Table](#) by the respective plan type and drug list where applicable.

Receipt of sample product does not satisfy any criteria requirements for coverage.

Medical Necessity Criteria

Somapacitan-beco subcutaneous injection (Sogroya) is considered medically necessary when ONE of the following is met:

- 1. Growth Hormone Deficiency in a Child or Adolescent.** Individual meets **ALL** of the following criteria:
 - A. Age 2.5 years or older
 - B. **ONE** of the following:

- i. Documentation of **BOTH** of the following:
 - a. Diagnostic evaluation including **BOTH** of the following:
 - I. Other pituitary hormone deficiencies (for example, thyroid, cortisol or sex steroids) have been ruled out and/or corrected prior to time of testing
 - II. **TWO** growth hormone stimulation tests performed with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon **AND** both tests show a growth hormone response of less than 10 ng/mL
 - b. Auxologic evaluation (stature and growth velocity data) including **ONE** of the following:
 - I. Height is more than two [2] standards of deviation (SD) below average for the population mean height for age and sex, and **ONE** of the following:
 - 1) One-year height velocity more than one standard of deviation (SD) below the mean for chronological age
 - 2) 2 years of age or older, and there is a decrease in height of more than 0.5 standards of deviation (SD) over one year
 - II. One-year height velocity is more than two standards of deviation (SD) below the mean for age and sex
 - III. Height velocity is more than 1.5 standards of deviation (SD) below the mean sustained over two years
- ii. Cranial or Whole Body irradiation
- iii. **BOTH** of the following:
 - a. **ONE** of the following:
 - I. Defined central nervous system pathology (for example, empty sella syndrome, interruption of pituitary stalk, hypoplasia of the pituitary gland, craniofacial developmental defects, pituitary or hypothalamic tumors)
 - II. Undergone tumor resection
 - b. **ONE** of the following:
 - I. **ONE** growth hormone stimulation test with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon **AND** the test shows a growth hormone response of less than 10 ng/mL
 - II. Deficiency in at least **ONE** other pituitary hormone (for example, adrenocorticotrophic hormone, thyroid-stimulating hormone, gonadotropin [luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency], or prolactin)
- iv. Congenital hypopituitarism
- v. Multiple pituitary hormone deficiencies and **BOTH** of the following:
 - a. **THREE** or more of the following pituitary hormone deficiencies: somatotropin (growth hormone), adrenocorticotrophic hormone, thyroid-stimulating hormone, gonadotropin (luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency), and prolactin
 - b. **ONE** growth hormone stimulation test with any of the following agents: levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon **AND** the test shows a growth hormone response of less than 10 ng/mL

Note: If the individual has had one growth hormone stimulation test and the peak growth hormone response was less than 10 ng/mL, this would satisfy criteria for an approval.

vi. Hypophysectomy (surgical removal of pituitary gland)

- C. Medication is prescribed by, or in consultation with, an endocrinologist
- D. Non-Covered Product Criteria is met, refer to below table(s)

Employer Group Non-Covered Products and Criteria:

Non-Covered Product	Criteria
Sogroya (somapacitan- beco)	ONE of the following: A. 2.5 to 17 years of age AND documented inadequate efficacy (following 6 months of therapy) or intolerance to Skytrofa [requires prior authorization] B. 18 years of age or older AND documented intolerance to BOTH of the following: i. Genotropin [requires prior authorization] ii. Omnitrope [requires prior authorization]

Individual and Family Plan Non-Covered Products and Criteria:

Non-Covered Product	Criteria
Sogroya (somapacitan- beco)	ONE of the following: A. Documented trial with inadequate efficacy (tried for 12 months and has a growth rate of less than 2 cm per year) with ONE of the following: i. Genotropin [requires prior authorization] ii. Humatrope [requires prior authorization] B. Documented intolerance to BOTH of the following: i. Genotropin [requires prior authorization] ii. Humatrope [requires prior authorization]

- 2. **Growth Hormone Deficiency in an Adult or Transition Adolescent.** Individual meets **ALL** of the following criteria:
 - A. According to the prescriber, somatropin is not being prescribed for anti-aging therapy or to enhance athletic ability or for body building
 - B. Documented diagnosis of growth hormone deficiency based on **ONE** of the following:
 - i. Childhood onset
 - ii. Adult onset that results from **ONE** of the following:
 - a. growth hormone deficiency alone or multiple hormone deficiencies (hypopituitarism) resulting from pituitary disease
 - b. hypothalamic disease
 - c. pituitary surgery
 - d. cranial radiation therapy
 - e. tumor treatment
 - f. traumatic brain injury
 - g. subarachnoid hemorrhage
 - C. **ONE** of the following criteria:
 - i. Individual has known perinatal insults OR congenital or genetic defects
 - ii. **ALL** of the following:
 - a. **THREE** or more of the following pituitary hormone deficiencies: adrenocorticotrophic hormone, thyroid-stimulation hormone, gonadotropin deficiency (luteinizing hormone and/or follicle stimulating hormone deficiency are counted as one deficiency), and prolactin

- b. The age and gender adjusted serum insulin-like growth factor-1 is below the lower limit of the normal reference range for the reporting laboratory
 - c. Other causes of low serum insulin-like growth factor-1 have been excluded (e.g., malnutrition, prolonged fasting, poorly controlled diabetes mellitus, hypothyroidism, hepatic insufficiency, oral estrogen therapy)
 - d. For an adult: Negative response to **ONE** of the following standard growth hormone stimulation tests:
 - 1) For insulin, levodopa, clonidine, arginine, or glucagon: growth hormone response of less than 5 ng/mL when measured by polyclonal antibody (RIA) or less than 2.5 ng/mL when measured by monoclonal antibody (IRMA) to one provocative stimuli of growth hormone release
 - 2) For macimorelin: **BOTH** of the following:
 - I. Maximum serum growth hormone level observed after stimulation of less than 2.8 ng/ml for the 4 blood draws
 - II. Body mass index (BMI) less than or equal to 40 kg/m²
- D. Medication is being prescribed by, or in consultation with, an endocrinologist
- E. Non-Covered Product Criteria is met, refer to below table(s)

Employer Group Non-Covered Products and Criteria:

Non-Covered Product	Criteria
Sogroya (somapacitan-beco)	Documented intolerance to BOTH of the following: <ul style="list-style-type: none"> 1. Genotropin [requires prior authorization] 2. Omnitrope [requires prior authorization]

Individual and Family Plan Non-Covered Products and Criteria:

Non-Covered Product	Criteria
Sogroya (somapacitan-beco)	Documented intolerance to BOTH of the following: <ul style="list-style-type: none"> 1. Genotropin [requires prior authorization] 2. Humatrope [requires prior authorization]

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Reauthorization Criteria

Continuation of somapacitan-beco (Sogroya) is considered medically necessary for **ALL** covered diagnoses when the above medical necessity criteria are met AND beneficial response is demonstrated by **ONE** of the following:

- 1. Less than 12 years of age: Height has increased by at least 2 cm/year in the most recent year
- 2. 12 years of age to 17 years of age and **BOTH** of the following:
 - a. Height has increased by at least 2 cm/year in the most recent year
 - b. Epiphyses are open
- 3. 18 years of age or older and **ALL** of the following:
 - a. Height has increased by at least 2 cm/year in the most recent year
 - b. Epiphyses are open
 - c. Mid-parental height has not been attained

Authorization Duration

Initial approval duration is up to 12 months.
Reauthorization approval duration is up to 12 months.

Conditions Not Covered

Any other use is considered experimental, investigational or unproven, including the following (this list may not be all inclusive):

- 1. Athletic Ability Enhancement.** Somatropin and related agents are not FDA-approved for athletic performance enhancement or for body building in non-athletes. Federal law prohibits the distribution or dispensing of somatropin or related agents for non-FDA approved uses.
- 2. Central Precocious Puberty.** Children with precocious puberty are often treated with gonadotropin releasing hormone (GnRH) agonists (Lupron® [leuprolide acetate injection]) to suppress pituitary gonadal activity, to slow the advancement of bone age (prevent premature fusion of the epiphyseal growth plates), and to improve adult height. In some patients, GnRH agonist therapy may result in marked deceleration of bone growth and may result in adult height that is less than the midparental height. Somatropin has been used in girls when growth velocity decreases or if it appears that the targeted adult height will not be attained. There are no large well-controlled trials on the efficacy and safety of adding somatropin to GnRH agonist therapy in these children or the effect on final height.
- 3. Congenital Adrenal Hyperplasia (CAH).** The Endocrine Society clinical practice guidelines on CAH due to steroid 21-hydroxylase deficiency recommend against the use of experimental treatment approaches outside of formally approved clinical trials. Children with predicted adult height standard deviation ≤ -2.25 may be considered for growth-promoting treatments in appropriately controlled trials.
- 4. Constitutional Delay of Growth and Puberty.** These children have delayed skeletal maturation and pubertal development. Administering somatropin does not increase adult height (which is usually normal). Short-term androgen therapy accelerates growth and the rate of pubertal advancement in boys.
- 5. Acute Critical Illness Due to Complications Following Surgery, Multiple Accidental Trauma, or with Acute Respiratory Failure.** In two placebo-controlled trials, in non-growth hormone deficient adults (n = 522) with these conditions, there was a significant increase in mortality (42% vs. 19%) in patients treated with somatropin compared to those on placebo.
- 6. Aging (i.e., Antiaging); To Improve Functional Status in Elderly Patients; and Somatopause.** Somatropin is not FDA-approved for anti-aging therapy, to improve functional status in elderly patients, or to treat somatopause. Federal law prohibits the distribution or dispensing of somatropin for non-FDA approved uses. There are no long-term studies assessing somatropin efficacy and safety for anti-aging therapy. Short-Page 8 of 19 Coverage Policy Number: 4012 term therapy with somatropin may improve some measures of body composition, including increased muscle mass, reduced total body fat, improved skin elasticity, and reduced rate of bone demineralization, but does not have positive effects on strength, functional capacity, or metabolism. Somatropin is associated with considerable adverse effects in non-growth hormone deficient adults (e.g., carpal tunnel syndrome, soft tissue edema, arthralgias, glucose intolerance, increased serum lipids). Another concern is the possible increased risk of cancer with long-term use of somatropin and the potentiating effects of IGFs on cancer. Somatropin is not indicated for the age-related decrease in growth hormone/IGF-1 status.
- 7. Chronic Fatigue Syndrome.** There is no evidence of GHD in chronic fatigue syndrome.
- 8. Corticosteroid-Induced Short Stature.** This includes a variety of chronic glucocorticoid-dependent conditions, such as asthma, Crohn's disease, juvenile rheumatoid arthritis, as well as after renal, heart, liver, or bone marrow transplantation. Short-term improvement in growth velocity in children with glucocorticoid-

induced suppression has been reported with somatropin therapy. Long-term data are not available. Children being considered for treatment with somatropin should be enrolled in studies that allow careful monitoring and data analysis.

- 9. Fibromyalgia.** In one placebo-controlled study, 120 non-GHD adult women with severe fibromyalgia and low levels of IGF-1 were randomized to somatropin 0.006 mg/kg/day for 12 months (dose was adjusted) or placebo for 6 months. Patients receiving placebo initially were switched to somatropin from Months 6 to 12 (open label). Standard therapy for fibromyalgia was continued. After 6 months, there were no differences between somatropin and placebo in the percentage of patients with fewer than 11 positive tender points, mean number of tender points, intensity of pain in every point evaluated, and other measures. After 12 months of somatropin therapy, 53% of patients had less than 11 positive tender points compared with 33% of patients who received placebo and then somatropin for 6 months ($P < 0.05$). At 18 months follow-up evaluation when somatropin was discontinued, impairment in pain perception worsened in both groups but to a lesser extent in the patients on somatropin for 12 months. Further controlled trials are needed with a longer duration, with different doses, and using the 2010 American College of Rheumatology criteria for fibromyalgia. Some patients with fibromyalgia may have adult GHD.
- 10. Human Immunodeficiency Virus (HIV)-Infected Patients with Alterations in Body Fat Distribution** (e.g., increased abdominal girth, lipodystrophy and excess abdominal fat, buffalo hump). Somatropin is not indicated for the treatment of HIV-associated adipose redistribution syndrome (HARS). HARS is a subset of HIV lipodystrophy and is defined as maldistribution of body fat characterized by central fat accumulation (lipohypertrophy) with or without lipoatrophy. In HARS, fat may also accumulate in the upper body subcutaneous area such as the dorsocervical area (buffalo hump). These changes may be associated with metabolic disturbances (insulin resistance, glucose intolerance, dyslipidemia) and belly image distress. Safety and efficacy are not established.
- 11. Infertility.** Clinical trials indicate that somatropin is not useful as an adjunct during in vitro fertilization, for induction of ovulation in polycystic ovary syndrome, or for assisted reproductive technology. The authors of a recent meta-analysis concluded there is no evidence of an increased chance of a live birth with use of somatropin.
- 12. Obesity.** Somatropin is not indicated for the treatment of obesity. Low growth hormone levels are a consequence of central obesity and not a cause. Obesity is associated with decreased basal and pulsatile release of growth hormone and decreased stimulated growth hormone release. Somatropin therapy does not have significant beneficial effects on obesity in persons without GHD and does not produce significant overall weight loss. Supraphysiologic doses of somatropin have been used to treat obesity. Effects of long-term therapy with somatropin are unknown.
- 13. Osteoporosis.** Guidelines for treatment or prevention of osteoporosis do not include recommendations for use of somatropin. In one double-blind trial, 80 postmenopausal women with osteoporosis (56% of patients [$n = 45/80$] had a history of fractures) were randomized to somatropin 0.33 mg/day or 0.83 mg/day or to placebo for three years.⁵⁰ The double-blind phase was 18 months and patients on somatropin continued drug for another 18 months and patients on placebo stopped at 18 months. Patients were compared with an age matched random population sample of women ($n = 120$). All patients received calcium 750 mg, vitamin D 400 units, and hormone replacement therapy. All women were followed for 10 years total. Bone mineral density increased in the patients receiving somatropin at years 4 and 5, and after 10 years, had decreased to similar levels as before treatment. At 10 years, 28% of women ($n = 22/80$) had had fractures. In the control group, fractures increased from 8% of patients at baseline to 32% of patients after 10 years. At 10 years, 41% of patients ($n = 33/80$) had stopped hormone replacement therapy; 23% had started bisphosphonates due to fractures, and 3% had received Forteo[®] (teriparatide injection). Larger studies are needed to determine the effects of somatropin therapy on bone mineral density and fractures in non-growth hormone deficient persons.

14. Other Off-label Uses [for example, celiac disease, chromosomal anomalies unless otherwise specified as covered (for example, but not limited to, deletion of chromosome 18q), Crohn's disease, cystic fibrosis, Down syndrome, hypophosphatemic rickets, juvenile rheumatoid arthritis, muscular dystrophy, primary or idiopathic IGF-1 deficiency, skeletal dysplasias, spinal cord defects]. There is insufficient evidence in the peer-reviewed published scientific literature to support the safety and efficacy of growth hormone therapy in these conditions. Additionally, federal law prohibits the distribution or dispensing of somatropin for non-FDA approved uses.

Background

OVERVIEW

Sogroya, a long-acting human growth hormone (hGH) analog, is indicated for the treatment of pediatric patients ≥ 2.5 years of age who have growth failure due to inadequate secretion of growth hormone (GH).¹ Sogroya is also indicated for the replacement of endogenous GH in adults with GH deficiency (GHD).

Disease Overview

GHD in Children and Adolescents

Sogroya is a hGH analog.¹ In children with GHD, somatropin is effective for increasing final adult height.² Somatropin therapy is recommended to normalize adult height and avoid extreme shortness in children and adolescents with GHD.² In addition to congenital causes, hypopituitarism may also be caused by radiation therapy; somatropin may be used to improve final height of children who have undergone radiation.^{3,4}

GHD in Adults or Transition Adolescents

Somatropin is indicated for the replacement of endogenous growth hormone in adults with GH, which may present in adults or children as GHD.¹¹ Patients with other anterior pituitary hormone deficiencies are likely to have GHD. In adults, the diagnosis of GHD usually is made in patients with signs and symptoms of hypothalamic-pituitary disease (endocrine, structural, and/or genetic causes); those who have received cranial irradiation or tumor treatment; or those with traumatic brain injury or subarachnoid hemorrhage.^{11,12} Onset may be in adulthood or childhood. In childhood, the goal of somatropin therapy is primarily for statural growth. When final adult height is attained, somatropin therapy is no longer required for statural growth. Transition is used to describe the period in adolescence after growth is completed and the need for continued replacement into adulthood is assessed. Confirmatory growth hormone stimulation testing may not be required in patients, such as with congenital/genetic GHD or multiple pituitary hormone deficiencies. When persistent GHD is documented after completion of adult height, somatropin therapy should be continued to attain full skeletal and muscle maturation during the transition period from childhood to adulthood.¹¹ In adults with GHD, somatropin replacement therapy improves abnormalities in substrate metabolism, body composition, and physical and psychosocial function.^{11,12} Growth hormone is not approved by the FDA for the treatment of other conditions in adults who may have a low growth hormone response to growth hormone provocative testing (such as obesity, aging, or depression) or to improve athletic performance.^{13,14}

Guidelines

Current guidelines do not specifically address Sogroya. Neither the Pediatric Endocrine Society guidelines for children and adolescents with GH deficiency² (2016) nor the GH Research Society guidelines on children with short stature¹⁵ (2019) recommend a specific GH product for GH deficiency. Both publications note that newer long-acting GH preparations may reduce the frequency of injections. The American Association of Clinical Endocrinologists and the American College of Endocrinology guidelines for management of GH deficiency in adults and patients transitioning from pediatric to adult care¹⁶ (2019) also do not prefer one GH agent over another. These guidelines state that when the clinician is suspicious of adult GH deficiency, establishing a diagnosis is essential before replacement with GH. Adult GH deficiency is associated with numerous adverse metabolic abnormalities (abdominal obesity, reduced lean body mass, increased peripheral insulin resistance, impaired cardiac performance) which may contribute to increased cardiovascular morbidity and mortality.

References

1. Sogroya® subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; April 2023.
2. Grimberg A, DiVall SA, Polychronakos C, et al; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. *Horm Res Paediatr*. 2016;86(6):361-397.
3. Melmed S. Idiopathic adult growth hormone deficiency. *J Clin Endocrinol Metab*. 2013;98:2187-2197.
4. Isfan F, Kanold J, Merlin E, et al. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA). *Bone Marrow Transplant*. 2012;47:684-693.
5. Clemmons DR, Molitch M, Hoffman AR, et al. Growth hormone should be used only for approved indications. *J Clin Endocrinol Metab*. 2014;99:409-411.
6. Carel JC, Eugster EA, Rogol A, et al on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009;123:e752-762.
7. Carel JC, Leger J. Precocious puberty. *N Engl J Med*. 2008;358:2366-2377.
8. Lin-Su K, Harbison MD, Lekarev O, et al. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. *J Clin Endocrinol Metab*. 2011;96:1710-1717.
9. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2018;103(11):4043-4088.
10. De Luca F, Argente J, Cavallo L, et al; International Workshop on Management of Puberty for Optimum Auxological Results. Management of puberty in constitutional delay of growth and puberty. *Pediatr Endocrinol Metab*. 2001;14 Suppl 2:953-957.
11. Molitch ME, Clemmons DR, Malozowski S, et al; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96:1587-1609.
12. Ho KK; 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. *Eur J Endocrinol*. 2007;157:695-700.
13. Melmed S. Idiopathic adult growth hormone deficiency. *J Clin Endocrinol Metab*. 2013;98:2187-2197.
14. Clemmons DR, Molitch M, Hoffman AR, et al. Growth hormone should be used only for approved indications. *J Clin Endocrinol Metab*. 2014;99:409-411.
15. Collett-Solberg PF, Ambler G, Backeljaw PF, et al. Diagnosis, genetics, and therapy of short stature in children: A growth hormone research society international perspective. *Horm Res Paediatr*. 2019;92(1):1-14.
16. Yuen K, Biller B, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. *Endocr Pract*. 2019;25(11):1191-1232.
17. Vance ML. Can growth hormone prevent aging? *N Engl J Med*. 2003;348:779-780.
18. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med*. 2007;146:104-115.
19. Cleare AJ, Sookdeo SS, Jones J, et al. Integrity of the growth hormone/insulin-like growth factor system is maintained in patients with chronic fatigue syndrome. *J Clin Endocrinol Metab*. 2000;85:1433-1439.
20. Cuatrecasas G, Alegre C, Fernandez-Solà J, et al. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. *Pain*. 2012;153:1382-1389.
21. Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. *Rheum Dis Clin North Am*. 2002;28:389-404.
22. Hart RJ, Rombauts L, Norman RJ. Growth hormone in IVF cycles: any hope? *Curr Opin Obstet Gynecol*. 2017;29(3):119-125.
23. Homburg R, Singh A, Bhide P, et al. The re-growth of growth hormone in fertility treatment: a critical review. *Hum Fertil (Camb)*. 2012;15:190-193.

24. Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. *Obes Res.* 2003;11:170-175.
25. Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a meta-analysis. *J Clin Endocrinol Metab.* 2009;94:130-137.
26. Krantz E, Trimpou P, Landin-Wilhelmsen K. Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: A 10-Year follow-up study. *J Clin Endocrinol Metab.* 2015;100:3251-3259.
27. Gillberg P, Mallmin H, Petren-Mallmin M, et al. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. *J Clin Endocrinol Metab.* 2002;87:4900-4906.

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2024 Cigna.